These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 22864966)

  • 1. Sulpiride and refractory panic disorder.
    Nunes EA; Freire RC; Dos Reis M; de Oliveira E Silva AC; Machado S; Crippa JA; Dursun SM; Baker GB; Hallak JE; Nardi AE
    Psychopharmacology (Berl); 2012 Sep; 223(2):247-9. PubMed ID: 22864966
    [No Abstract]   [Full Text] [Related]  

  • 2. Amisulpride monotherapy in a patient with clozapine-resistant schizophrenia.
    Pehlivanidis A; Spyropoulou AC; Tourkantonis A; Papadimitriou GN
    Clin Neuropharmacol; 2010 May; 33(3):168. PubMed ID: 20502137
    [No Abstract]   [Full Text] [Related]  

  • 3. Amisulpride treatment for clozapine-induced sialorrhea.
    Praharaj SK; Sarkar S; Sinha VK
    J Clin Psychopharmacol; 2009 Apr; 29(2):189-90. PubMed ID: 19512987
    [No Abstract]   [Full Text] [Related]  

  • 4. Recent developments in the management of psychosis.
    Hoes MJ
    Pharm World Sci; 1998 Jun; 20(3):101-6. PubMed ID: 9618732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-uniform blockade of intrastriatal D2/D3 receptors by risperidone and amisulpride.
    Stone JM; Bressan RA; Erlandsson K; Ell PJ; Pilowsky LS
    Psychopharmacology (Berl); 2005 Aug; 180(4):664-9. PubMed ID: 15719226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of dopamine D2/D3 receptor antagonism on human planning and spatial working memory.
    Naef M; Müller U; Linssen A; Clark L; Robbins TW; Eisenegger C
    Transl Psychiatry; 2017 Apr; 7(4):e1107. PubMed ID: 28440817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials.
    Leucht S
    Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S15-20. PubMed ID: 14972080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15.
    Gyertyán I; Sághy K; Laszy J; Elekes O; Kedves R; Gémesi LI; Pásztor G; Zájer-Balázs M; Kapás M; Agai Csongor E; Domány G; Kiss B; Szombathelyi Z
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Nov; 378(5):529-39. PubMed ID: 18548231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frontal fasciculi and psychotic symptoms in antipsychotic-naive patients with schizophrenia before and after 6 weeks of selective dopamine D2/3 receptor blockade.
    Ebdrup BH; Raghava JM; Nielsen MØ; Rostrup E; Glenthøj B
    J Psychiatry Neurosci; 2016 Mar; 41(2):133-41. PubMed ID: 26599135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sulpiride, a D2/D3 blocker, reduces cataplexy but not REM sleep in canine narcolepsy.
    Okura M; Riehl J; Mignot E; Nishino S
    Neuropsychopharmacology; 2000 Nov; 23(5):528-38. PubMed ID: 11027918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Striatal D(2/3) Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate With Treatment Outcome.
    Wulff S; Pinborg LH; Svarer C; Jensen LT; Nielsen MØ; Allerup P; Bak N; Rasmussen H; Frandsen E; Rostrup E; Glenthøj BY
    Schizophr Bull; 2015 Sep; 41(5):1143-52. PubMed ID: 25698711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levosulpiride. Levopraid, RV 12309.
    Drugs R D; 1999 Oct; 2(4):247-8. PubMed ID: 10659401
    [No Abstract]   [Full Text] [Related]  

  • 13. Dopaminergic challenges in social anxiety disorder: evidence for dopamine D3 desensitisation following successful treatment with serotonergic antidepressants.
    Hood SD; Potokar JP; Davies SJ; Hince DA; Morris K; Seddon KM; Nutt DJ; Argyropoulos SV
    J Psychopharmacol; 2010 May; 24(5):709-16. PubMed ID: 18838500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15.
    Kiss B; Laszlovszky I; Horváth A; Némethy Z; Schmidt E; Bugovics G; Fazekas K; Gyertyán I; Agai-Csongor E; Domány G; Szombathelyi Z
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Nov; 378(5):515-28. PubMed ID: 18551280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients.
    Bressan RA; Erlandsson K; Jones HM; Mulligan R; Flanagan RJ; Ell PJ; Pilowsky LS
    Am J Psychiatry; 2003 Aug; 160(8):1413-20. PubMed ID: 12900302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 5-HT2 receptor profiles of antipsychotics in the pathogenesis of obsessive-compulsive symptoms in schizophrenia.
    Kim SW; Shin IS; Kim JM; Youn T; Yang SJ; Hwang MY; Yoon JS
    Clin Neuropharmacol; 2009; 32(4):224-6. PubMed ID: 19644229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remediation of attentional dysfunction in rats with lesions of the medial prefrontal cortex by intra-accumbens administration of the dopamine D(2/3) receptor antagonist sulpiride.
    Pezze MA; Dalley JW; Robbins TW
    Psychopharmacology (Berl); 2009 Jan; 202(1-3):307-13. PubMed ID: 18985321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophrenia.
    Schmidt ME; Kent JM; Daly E; Janssens L; Van Osselaer N; Hüsken G; Anghelescu IG; Van Nueten L
    Eur Neuropsychopharmacol; 2012 Oct; 22(10):721-33. PubMed ID: 22464973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study.
    Shiloh R; Zemishlany Z; Aizenberg D; Radwan M; Schwartz B; Dorfman-Etrog P; Modai I; Khaikin M; Weizman A
    Br J Psychiatry; 1997 Dec; 171():569-73. PubMed ID: 9519099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Why can low doses of sulpiride counteract depression?
    Okada F
    J Clin Psychopharmacol; 1995 Dec; 15(6):442-3. PubMed ID: 8748435
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.